Using tiny particles in blood and cerebrospinal fluid to improve the diagnosis and treatment of childhood brain tumours
Dr Timothy Ritzmann aims to improve ependymoma care and treatment by harnessing the potential of extracellular vesicles.
Stopping the alpha - a potential new treatment approach for osteosarcoma
Professor Plevin and Dr Margaret Cunningham will investigate an enzyme that might play a role in osteosarcoma development, and see whether this could form the basis of a new type of treatment.
Harnessing the immune system to treat Ewing sarcoma in the lungs
Dr Jonathan Fisher aims to create an 'off the shelf' version of immunotherapy to for hard-to-treat Ewing sarcoma.
Understanding new treatment options for when treatment for neuroblastoma doesn’t work or the cancer grows back
Dr Jess Morgan at the University of York will review the latest experimental treatments for hard-to-treat neuroblastoma to help with decision-making.
Understanding existing research about ambulatory chemotherapy for children and young people
Dr Jess Morgan at the University of York hopes to understand what we already know about using portable chemotherapy pumps for children with cancer.
Tracking individual osteosarcoma cells to understand how they dodge chemotherapy
Dr Lucia Cottone at University College London hopes to understand how osteosarcoma cells become resistant to chemotherapy, which has a big impact on patient survival.
Exploring how osteosarcoma cells spread and survive elsewhere in the body
Dr Olivier Pardo at Imperial College London aims to find out how osteosarcoma cells survive the bloodstream and spread elsewhere in the body.
Optimising drug treatment for childhood cancer patients
It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.
Investigating a new way of treating poor-prognosis rhabdomyosarcoma
Evaluating a novel protein methyltransferase inhibitor for poor-prognosis rhabdomyosarcoma therapy